# Bioavailability Study of EVEGYN 600 mg/1000 mg/100 mg Vaginal Ovule

> **NCT05361369** · PHASE1 · COMPLETED · sponsor: **Exeltis Turkey** · enrollment: 18 (actual)

## Conditions studied

- Bioavailability

## Interventions

- **DRUG:** EVEGYN 600 mg/1000 mg/100 mg Vaginal Ovule

## Key facts

- **NCT ID:** NCT05361369
- **Lead sponsor:** Exeltis Turkey
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-09
- **Primary completion:** 2022-05-13
- **Final completion:** 2023-03-15
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-02-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05361369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05361369, "Bioavailability Study of EVEGYN 600 mg/1000 mg/100 mg Vaginal Ovule". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05361369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*